Retatrutide Beats Ozempic on Weight Loss and A1c in TRANSCEND-T2D-2, Lilly Reports
Retatrutide, an investigational triple-agonist peptide from Eli Lilly and Company, produced roughly double the weight loss of Ozempic (semaglutide) 2 mg and a larger A1c reduction in adults with type 2 diabetes, according to company-reported topline results from the head-to-head phase 3 TRANSCEND-T2D-2 trial. The findings, announced by Lilly and reported by Medscape, compare weekly retatrutide 9 mg and 12 mg against the highest approved semaglutide dose for type 2 diabetes over an 80-week period.
The result matters to the peptide therapy and research peptide sector because it is the first randomized head-to-head data set positioning a triple GIP/GLP-1/glucagon receptor agonist directly against the market-leading GLP-1 receptor agonist. It also arrives while retatrutide remains unapproved by the FDA or any other regulatory body, a status that keeps the molecule inside research and investigational channels rather than legitimate clinical supply.
What happened in TRANSCEND-T2D-2
TRANSCEND-T2D-2 randomized participants with type 2 diabetes to weekly injections of retatrutide 9 mg, retatrutide 12 mg, or Ozempic 2 mg. Lilly’s topline release reports that participants on retatrutide lost an average of 44.3 lb (19.5%) at 9 mg and 47.4 lb (20.9%) at 12 mg, compared with 20.9 lb (9.4%) among participants taking Ozempic. At 80 weeks, both retatrutide doses reduced A1c by an average of 2.2 percentage points versus 1.8 points with Ozempic.
Lilly also states that retatrutide delivered greater improvements than Ozempic across certain cardiovascular risk factors, including non-HDL cholesterol, triglycerides, and systolic blood pressure. The company did not disclose effect sizes for those secondary measures in the topline announcement, and no cardiovascular outcome data were reported.
All efficacy and safety figures described here come from Lilly’s topline announcement as reported by Medscape. The article cites no independent verification, no full peer-reviewed publication, and no statistical-significance testing for the between-arm comparisons. Readers should treat the numbers as company-reported until the full trial data are presented or published.
Key numbers at a glance
| Endpoint | Retatrutide 9 mg | Retatrutide 12 mg | Ozempic (semaglutide) 2 mg |
|---|---|---|---|
| Average weight loss | 44.3 lb (19.5%) | 47.4 lb (20.9%) | 20.9 lb (9.4%) |
| A1c reduction at 80 weeks | 2.2% | 2.2% | 1.8% |
| Dysesthesia | 4.8% | 6.5% | 2.7% |
| Discontinuation due to adverse events | 4.8% | 7.9% | 2.7% |
| Diarrhea | 28.3% | 32.7% | 26.4% |
| Nausea | 21.2% | 23.8% | 21.3% |
| Constipation | 14.2% | 13.1% | 19.8% |
How the safety profile compares
Gastrointestinal adverse events were the most common in all arms and broadly similar in pattern. Lilly reported diarrhea in 28.3% and 32.7% of retatrutide participants at 9 mg and 12 mg versus 26.4% with Ozempic, nausea in 21.2% and 23.8% versus 21.3%, constipation in 14.2% and 13.1% versus 19.8%, vomiting in 10.2% and 15% versus 13.2%, and dyspepsia in 10.4% and 8.5% versus 11.6%.
The more distinctive signal was dysesthesia, a sensory disturbance reported in 4.8% of the 9 mg arm and 6.5% of the 12 mg arm versus 2.7% with Ozempic. Urinary tract infections occurred in 5.8% and 4.2% versus 5.8%. Lilly states that the majority of adverse events were mild to moderate and resolved during treatment.
Treatment discontinuation due to adverse events was 4.8% at 9 mg and 7.9% at 12 mg, compared with 2.7% with Ozempic. The absolute difference in the 9 mg arm is small, but the 12 mg figure is roughly three times the comparator rate, a gap that may matter for real-world tolerability and titration strategy once full data are available.
Why it matters for peptide therapy and research peptides
For the peptide therapy industry, the headline is not simply a bigger weight-loss number. It is a signal about where incretin peptide development is heading: from single-receptor GLP-1 agonism toward multi-receptor molecules that also engage GIP and glucagon pathways. Retatrutide is designed as a triple agonist, a mechanism that distinguishes it from semaglutide, which acts on the GLP-1 receptor, and from tirzepatide, which activates both GIP and GLP-1 receptors.
That distinction has practical consequences for clinics, telehealth operators, and compounding stakeholders. Any molecule in this class that is not approved cannot lawfully be prescribed or dispensed as a treatment, and compounded versions of an investigational drug raise separate legal and quality questions. Clinics evaluating their formularies should verify approval status for the specific drug product, formulation, and indication rather than relying on supplier statements or the presence of an ingredient in a database.
Supply-side interest is already visible. Research peptide suppliers and gray-market sellers have promoted retatrutide despite its unapproved status. According to Lilly, anyone offering the investigational drug to consumers is breaking the law, and the FDA has already issued warning letters to some of the companies involved. For buyers, a research-use designation does not establish sterility, safety, or authorization for human administration, and a certificate of analysis does not independently establish clinical safety or regulatory approval.
Industry observers note that demand pressure of this kind typically flows into two channels: legitimate clinical trials and, less desirably, unapproved online supply. The second channel is where quality risk concentrates, including uncertain identity, concentration errors, peptide-related impurities, and inadequate manufacturing controls. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
Research and market context
The TRANSCEND-T2D-2 readout lands in a competitive landscape where head-to-head data increasingly drive formulary and prescribing decisions. Lilly is separately comparing retatrutide with tirzepatide in TRIUMPH-5, an ongoing phase 3 trial in adults with obesity with or without type 2 diabetes. Results from that trial are pending and will be central to any claim that retatrutide is superior to existing dual agonists.
Kenneth Custer, PhD, executive vice president and president of Lilly Cardiometabolic Health, said in the announcement that based on these results and those from across the phase 3 program, the company believes retatrutide, if approved, could shift the treatment paradigm for people living with type 2 diabetes, obesity, and related cardiometabolic conditions. That statement is an executive opinion explicitly conditioned on approval; it is not an established clinical or commercial outcome, and it depends on regulatory review, pricing, payer access, and long-term safety data.
For the manufacturing and API side of the peptide economy, a triple agonist adds analytical complexity. Longer or more modified sequences, impurity control, and batch-to-batch consistency all become more demanding, and buyers should expect batch-specific analytical documentation covering identity, purity, and impurity profile. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
Analysts watching the sector will also focus on tolerability-driven discontinuation, since a higher dropout rate can erode the real-world advantage suggested by efficacy figures. Whether the dysesthesia signal is dose-dependent, transient, or persistent is not addressed in the topline release, and the mechanism behind it is not explained.
What comes next
- Full TRANSCEND-T2D-2 data, including statistical significance, baseline characteristics, and secondary endpoints, have not been published or independently verified.
- TRIUMPH-5, the retatrutide-versus-tirzepatide phase 3 trial, is ongoing; its results will test the competitive positioning of the triple agonist.
- Regulatory status is unchanged: retatrutide is not approved by the FDA or any other regulatory body, and enforcement against online sellers remains active.
- Clinics and telehealth operators should continue to verify approval status and labeling for each specific product rather than extrapolating from topline press releases.
Until peer-reviewed data and regulatory decisions arrive, the practical takeaway for the peptide therapy sector is caution paired with attention: the efficacy signal is large, the safety profile is directionally familiar but not identical, and the legal status of the molecule outside trials has not changed. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.